Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New agents for Type 2 diabetes.

M Nattrass1, C J Bailey

  • 1Diabetes Resource Centre, Selly Oak Hospital, Birmingham, UK.

Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism
|April 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future.

Clinical pharmacology and therapeutics·2015
Same author

Safety of antidiabetes medications: An update.

Clinical pharmacology and therapeutics·2015
Same author

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.

Diabetes, obesity & metabolism·2014
Same author

A cotyledon slice system for the electron autoradiographic study of the synthesis and intracellular transport of the seed storage protein of Vicia faba.

Planta·2014
Same author

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

Diabetes, obesity & metabolism·2012
Same journal

Inhibin B in the assessment of seminiferous tubular function.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Post-Chernobyl thyroid carcinoma in children.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Surgical approach to thyroid nodules and cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Diagnosis and treatment of medullary thyroid cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Management of undifferentiated thyroid cancer.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
Same journal

Papillary and follicular thyroid carcinoma.

Bailliere's best practice & research. Clinical endocrinology & metabolism·2001
See all related articles

New treatments for Type 2 diabetes mellitus aim to improve metabolic profiles and reduce complications. Novel agents targeting insulin resistance and beta-cell function are being developed to complement existing therapies.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Current Type 2 diabetes mellitus treatments offer partial metabolic improvement and complication reduction.
  • Novel therapeutic strategies are needed to address the underlying pathogenesis of insulin resistance and beta-cell failure.

Purpose of the Study:

  • To review emerging therapeutic agents for Type 2 diabetes mellitus.
  • To discuss novel mechanisms of action targeting key diabetes pathologies.

Main Methods:

  • Review of recently introduced and pipeline pharmacologic agents for Type 2 diabetes.
  • Analysis of drug classes including insulin secretagogues, insulin sensitizers, lipase inhibitors, and satiety inducers.

Main Results:

  • Repaglinide synchronizes insulin secretion to reduce post-prandial hyperglycemia.

Related Experiment Videos

  • Thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) activate PPARgamma, enhancing insulin sensitivity.
  • Orlistat and sibutramine offer potential benefits for glycemic control in obese patients through weight reduction.

    • Conclusions:

    • Emerging agents offer novel approaches to managing Type 2 diabetes.
    • While promising, the long-term impact of these new agents on halting or reversing disease progression requires further investigation.